^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PT217

i
Other names: PT217, PT-217, PT 217
Company:
Phanes Therap
Drug class:
CD47 inhibitor, DLL3 inhibitor
6ms
A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (clinicaltrials.gov)
P1/2, N=61, Recruiting, Phanes Therapeutics | Phase classification: P1 --> P1/2
Phase classification
|
EGFR (Epidermal growth factor receptor) • DLL3 (Delta Like Canonical Notch Ligand 3)
|
PT217
over1year
A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (clinicaltrials.gov)
P1, N=58, Recruiting, Phanes Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Jun 2023
Enrollment open • Trial initiation date • Metastases
|
EGFR (Epidermal growth factor receptor) • DLL3 (Delta Like Canonical Notch Ligand 3)
|
DLL3 expression
|
PT217
almost2years
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • DLL3 (Delta Like Canonical Notch Ligand 3)
|
DLL3 expression
|
PT217
over2years
PT217, an anti-DLL3/anti-CD47 bispecific antibody, exhibits anti-tumor activity through novel mechanisms of action (AACR 2022)
Furthermore, PT217 exhibits regular mAb-like manufacturability in process development and CMC. We expect to initiate a phase 1 trial to target SCLC in the first half of 2022.
IO biomarker
|
CD47 (CD47 Molecule) • DLL3 (Delta Like Canonical Notch Ligand 3) • SIRPA (Signal Regulatory Protein Alpha)
|
DLL3 expression
|
PT217